Company / EPS (Diluted)
Arcus Biosciences, Inc. EPS (Diluted) History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest EPS (Diluted)
-$4.15
FY2025
5-year range
-$4.15 / $0.71
FY2021-FY2025
Trend
-11.9%
vs FY2024
Sector context
#166 of 204
Health Care
What the data says
Arcus Biosciences, Inc.'s eps (diluted) of $-4.15 is lower than 81% of companies in the Health Care sector (FY2025). Declined from $0.71 to $-4.15 over the past 2 years.
Based on SEC 10-K filings.
-4.15 in FY2025.
Declined from $0.71 to $-4.15 over the past 2 years.
Health Care sector context is included.
EPS (Diluted) over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 19% in Health CareTop 81% of 204This company -$4.15 Sector average -$0.89
▼
-368.3% below sector average
Key checks
Key Insights
- In FY2025, eps (diluted) decreased 11.9% year-over-year.
- Ranks #166 out of 204 companies in the Health Care sector.
- Peak eps (diluted) was recorded in FY2023.
- Lowest eps (diluted) in the period was in FY2018.
Company context
Key Data Points
- Low Piotroski F-Score: 0/9 (multiple financial health concerns)
- Altman Z-Score -0.93 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | EPS (Diluted)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$4.15 | -11.9% |
| FY2024 | -$3.71 | -622.5% |
| FY2023 | $0.71 | +131.7% |
| FY2022 | -$2.24 | -16.1% |
| FY2021 | -$1.93 | -35.0% |
| FY2020 | -$1.43 | +0.0% |
| FY2019 | -$1.43 | +93.1% |
| FY2018 | -$20.80 | - |
| FY2017 | - | - |
| FY2016 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026